Baxter Theranova: More Middle Molecules, Less Albumin Loss
Baxter’s new dialyzer mimics the function of natural kidneys more closely, removing more middle molecules with no replacement fluid needed—and minimal loss of vital albumin. The new expanded hemodialysis (HDx) therapy has been tested in the UK, where it reduced beta-2 microglobulin levels by more than 11%
Read the full article » | Posted 12-14-2017
Related Articles
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
- FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026
- Drs. Monica Farcus and Jeffrey Perl Win the Mitchell Award for Health System Innovation Posted 01-16-2026
- Nephrodite Wins FDA Breakthrough Device Designation for “Holly” Posted 01-16-2026

